利妥昔单抗（Rituximab）作为首个获批的抗肿瘤单抗药物，通过靶向CD20抗原显著改善了非霍奇金淋巴瘤患者的预后。将FITC与该单抗结合，不仅保留了其免疫识别能力，更赋予实时成像功能，为肿瘤靶向治疗提供可视化导航。 标记技术优化 FITC通过其异硫氰酸基团 ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

The Phase III MITIGATE trial demonstrated that Uplizna (inebilizumab) significantly reduces the risk of flares, lowers ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. This study aimed to optimize and validate a cationization method for the Fab’ fragment ...

Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands. Its biosimilar of Roche’s ...

For patients transitioning from rituximab to ravulizumab, meningococcal vaccination can be safely done within 6 months after ...

Over 10 days, the porcine liver produces bile and porcine albumin, maintains stable blood flow, and shows no signs of ...

Rituximab is a licensed therapy for granulomatosis with polyangiitis and microscopic polyangiitis but there is limited experience of rituximab in EGPA. Methods EGPA patients from a tertiary centre who ...

She was admitted to hospital as an emergency with prolonged and painful extensor spasms affecting the neck and back, arms, and legs. The disease had progressed despite a favourable initial response to ...

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

Importantly, we detail the novel use of a triplet therapy combining a non-covalent BTKi, venetoclax, and rituximab, demonstrating promising outcomes that provide valuable insights into managing this ...